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Abstract. The purpose of the research was to determine the in vivo effectiveness of mebendazole over 
dog strongyls through Faecal Egg Count Reduction Test (FECRT); the obtained data being statistically 
interpreted. Ten dogs had been treated with mebendazol; faecal samples were taken before and after treatment 
over a period of 7 days. The obtained results highlighted an average ante-therapeutic(AT) intensivity of 240 
EPG, respectively 370 LPG, and the extensivity being of 100% regardless of the method of calculation. Both 
values becoming null after the 14th day after treatment. The analysis of the statistical indexes quantified through 
the level o the EPG show a reduction percentage of 100% in a 14-20 day period post-therapeutic (PT). The value 
of the probability index calculated through the comparison of AT show significant statistical value. The values of 
the statistical indexes quantified through LPG shows a reduction percentage of 100% over the length of the 
experiment the probability index being of 0.00016 regardless of the PT time period. The global analysis of the 
data obtained by means of FECRT show a good therapeutic effectiveness of mebendazole, with no signs of 




Taking into account the high risk of contamination in humans with Ancylostoma and 
strongyls species coming from dogs, a thorough understanding of the utilized medication 
effectiveness in preventing and treating the tow diseases is needed (Genta, 1989; Grove, 1996; 
Zanc 2001). The lack of a periodic anthelmintical medication or further confirmation of the 
effectiveness of the treatment determine a high risk if human infestation (Bowman, 1999; 
Adams, 2001). On a global scale, establishing the existence of an in vivo drug-resistance of 
the strongyles to probenzimidazoles and benzimidazoles derivatives is done by tow tests: the 
global parasitical count and Faecal Egg Count Reduction Test (FECRT) (Conder and 
Campbell, 1995; Davies and Schwalbach, 2000; Monahan, 2000; Cernea 2007). The purpose 
of the research was to calculate the intensivity and extensivity of strongiloidosis before 
treatment (AT); establishing the in vivo effectiveness of mebendazole or the existence of 
drug-resistance to this anthelmintic; statistical analysis of the obtained data; identifying the 
strongyl species. 
 
MATERIAL AND METHOD 
 
The research was carried out between November and December 2006, on a number of 
10 dogs from Cluj-Napoca, from which feces samples were taken before therapy (AT), 
establishing the intensiveness and extensiveness of the strongyloidosis. Later on, a 
mebendazole (MBZ) based medication was applied; feces samples being collected 4 times at 
7 days intervals. In each test stage (PT 7-14-21 and 28 days) the intensivity and extensivity of 
the strongyloidosis was determined through quantifying EPG or after incubation LPG. All this 
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data were statistically interpreted calculating he standard deviation, the reduction percentage, 
the 95% trust interval and the probability index ”p” compared with AT values (Coles et all, 
1992). The statistical validity of the data obtained through the T Welch was achieved by 
applying normality tables which use the calculation of the Kolmogorov-Smirnov index 
[Motulsky et all, 1999; Motulsky, 2004].. In case of all the calculated and compared 
variations, the results passed the normality tables, being considered correct, and the database 
used with sufficient variables. The samples obtained from the dogs were analyzed using the 
McMaster, Stoll and feces cultures. 
 
RESULTS AND DISCUSSIONS 
 
From the examined group of 10 dogs, 4 females, 6 males, aged between 1 and 7 years, 
copro-parasitological samples were taken before (AT) and after treatment (PT), thus 
collecting the samples 4 times at 7 day intervals. These have shown that all tested dogs were 
positive regarding Ancylostomidae and Strongilidae infestation; the number of EPG varying 
between 100 and 500, and LPG between 200 and 600. AT intensivity determined through the 
McMaster method was of 240 EPG, respectively 370 LPG (Table 1)  
 
AT and PT results obtained through the McMaster and Stoll methods from the MBZ treated dogs (Cluj-
Napoca November-December 2006)  
Table 1. 








EPG LPG EPG LPG EPG LPG EPG LPG EPG LPG 
1 M 3 200 200 0 0 0 0 0 0 0 0 
2 M 5 100 200 0 0 0 0 0 0 0 0 
3 M 2 500 600 100 0 0 0 0 0 0 0 
4 M 1 400 600 100 0 0 0 0 0 0 0 
5 F 4 100 200 0 0 0 0 0 0 0 0 
6 F 4 200 400 0 0 0 0 0 0 0 0 
7 F 8 300 500 0 0 0 0 0 0 0 0 
8 M 7 200 200 0 0 0 0 0 0 0 0 
9 F 7 100 200 0 0 0 0 0 0 0 0 
10 M 5 300 600 0 0 0 0 0 0 0 0 
Average 240 370 20 0 0 0 0 0 0 0 
Intensivity 240 370 100 0 0 0 0 0 0 0 
Extensivity 100 100 20 0 0 0 0 0 0 0 
Standard deviation  134.99 188.86 42.16 0 0 0 0 0 0 0 
 
The analysis of the extensivity showed a percent of 100% regardless of the method of 
determining the infestation (EPG or LPG). After 7 days PT is noticed an intensiveness of 
100% EPG and an extensivity of 20%, the same parameters being nil in case of LPG. The 
explanation that in certain individuals it has been noticed the presence of eggs in the feces 
samples but not larva is found in the action of the benzimidazoles on eggs and larva, thus the 
eggs are no longer viable. The decreasing trend of the number of EPG and LPG, PT is kept up 
to 28 days, the value of extensivity and intensivity being nil (table 1). This dramatic evolution 
 93 
of the EPG and LPG reflects a good effectiveness of MBZ against ancylostomosis and 
strongyloidosis in the treated dogs. As a result in case of this treated group the usage of 
benzimidazole derivatives can be recommended for the moment without the risk of treatment 
disappointment. It is recommended that test be carried out twice a year to determine the 
effectiveness of varied drug groups through the feces larval reducing test, this way the drug-
resistance phenomena of the ancylostomes and strongyls to the usual treatment can be 
avoided. 
The effectiveness of MBZ was confirmed through the statistical indexes, through the 
quantification of EPG and LPG, thus the statistical evaluation of the reduction percentage, the 
95% trust interval and the probability index ”p”, in comparison with AT values highlights for 
EPG values that confirm a high MBZ effectiveness (table 2). After the 7 day interval the value 
of the reduction percentage was of 91.67%, thus being under the lower limit of 95%. The 
lower limit of the 95% (Inf L 95% T I.) trust interval was in the 7th day PT under the lower 
limit (90%), managing a value of 66% (table 2). In the 14th, 21st and 28th day PT the 
calculated reduction percentage through EPG was of 100% which shows a high effectiveness 
of MBZ. Calculating the probability index ”p” in the PT period compared with AT had been 
in all stages of the analysis (from the 7th to the 28th day PT) ”highly significant” (table 2). 
Quantifying the statistical index through the levels of LPG (AT and PT), shows a reduction 
percentage of 100% regardless of the analyzed PT period (table 3). In this case too the 
probability index ”p” shows ”highly significant” differences. This data is in accordance with 
the statistical indexes calculated through OPG, thus confirming that in the studied dogs MBZ 
based medication is effective from a therapeutic point of view. 
 
The values of statistical indicators for the in vivo quantification of the drug-resistance 
phenomena in the studied dogs treated with MBZ (EPG) (Cluj-Napoca, November-December 2006) 
Table 2. 
 PT - 7 day PT - 14 day PT - 21 day PT - 28 day 
Reduction %  91.67 100 100 100 
Inf L 95% T I.  66    
Sup L 95%. T. I.  98    
Probability index”p”  
(level of comparison AT) 0.000085 0.000325 0.000325 0.000325 
 
 
The values of statistical indicators for the in vivo quantification of the drug-resistance 
phenomena in the studied dogs treated with MBZ (LPG) (Cluj-Napoca, November – December 2006) 
Table 3.  
 PT - 7 day PT - 14 day PT - 21 day PT - 28 day 
Reduction %  100 100 100 100 
Inf L 95% T I.      
Sup L 95%. T. I.      
Probability index”p”  
(level of comparison AT) 0.000160 0.000160 0.000160 0.000160 
 
 
Through copro-parasitological examination done AT and PT 3rd stage larva belonging to 









3rd stage larva belonging to the Strongylida Phylum, isolated after 14 days 




3rd stage larva belonging to the Strongylida Phylum, isolated after 14 days 





The research was carried out between November and December 2006, on a number of 
10 dogs from Cluj-Napoca, with the purpose of testing the therapeutic effectiveness of MBZ 
against dog Strongyloidosis highlighted the following: 
 
The AT average intensivity reached a level of 240 EPG, respectively 370 LPG, and the 
extensivity reached 100%, regardless of the method of calculation. Both intensivity and the 
extensivity became nil from the 14th day PT. 
 
Analysis of the statistical indexes quantified through EPG show a reduction percentage 
of 100% in the 14th to 28th day PT time interval. The value of the probability index calculated 
through the comparison with AT show extremely important statistical values. 
 
The index values quantified through LPG levels show a percent of reduction of 100% 
over the length of the whole experiment the probability index being 0.00016, regardless of the 
studied PT interval. 
 
The global analysis of the data obtained through the FRCRT test shows a good 
therapeutic effectiveness of mebendazole, that does not show drug-resistance phenomena 
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